BioSpace News Archive

The company’s common stock will begin trading on the Nasdaq under the ticker symbol “SCPH” today.

Management will host a conference call on Tuesday, November 21, 2017 at 9:00am to review financial results and provide a corporate update.

The integration of N-of-One and Sunquest Mitogen will allow pathologists in hospitals and reference laboratories to streamline delivery of time-critical, case-specific genetic reports with high-quality clinical interpretation for NGS panels of all sizes.

These awards were granted pursuant to the Rigel PharmaInducement Plan, as amended, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Morgan Stanley acted as joint book-running managers for the offering.

A new real-world analysis of adults with type 2 diabetes and established CVD shows adult patients who initiated therapy with INVOKANA or another SGLT2i had a 43 percent reduced risk for ACM and hospitalization for HHF after an average of 1.6 years, compared to similar patients who initiated treatment with a non-SGLT2i medication using an ITT approach.

All comparative amounts in brackets refer to the outcome of InDex overall activities during the corresponding period 2016.

The Company further announces that current Non-Executive Directors, Matthew Hammond and Daniel Hegglin, will retire from the Board effective today, following the successful completion of the Company’s recent financing.

In return for the payment to Acorda, HCR obtains the right to receive royalty revenue on FAMPYRA payable by Biogen, up to an agreed upon threshold of royalties.